RE:News NeutriSci Announces Successful Completion of R&D in PreIt this R&D different than the CBN R&D?
May 10, 2021 / NeutriSci International Inc. is pleased to announce the Phase 1 R&D completion of a newly developed Cannabinol (CBN) product for the US marketplace. In conjunction with its contract manufacturing partner Pacwest, the completion of Phase 1 used NeutriSci's IP, technologies, and ingredients to create a finished CBN tablet product.